FDA OKs Ubrogepant (Ubrelvy) for Acute Migraine Treatment FDA OKs Ubrogepant (Ubrelvy) for Acute Migraine Treatment

Ubrogepant is the first drug in the class of oral calcitonin gene-related peptide receptor antagonists approved for the acute treatment of migraine.FDA Approvals
Source: Medscape Neurology and Neurosurgery Headlines - Category: Neurology Tags: Neurology & Neurosurgery News Alert Source Type: news